Healthcare and Life Science
TTP introduces Cellular Origins, a TTP Company focussed on delivering scalable manufacture of cell and gene therapies
TTP plc (TTP), a leading independent technology and product development company, has today announced the launch of Cellular Origins, a TTP Company. Cellular Origins is a TTP spin-out, created to enable scalable, cost-effective and efficient manufacture of cell and gene therapies. Cellul...
Avacta Announces Successful Completion of Fourth Dose Escalation in AVA6000 Phase 1 Clinical Study
Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics announces that AVA6000 continues to show a very favourable safety profile in the fourth dose cohort of the ALS-6000-101 dose escalation phase 1 clinical trial. A...
Taking the Sting out of Vaccines
Cast your mind into the future and imagine the world in the grips of the next global respiratory pandemic. We have the monumental task of vaccinating the world against a novel pathogen. How should we achieve this? ...
Robot-assisted surgical trends in 2023 and beyond
Robotic-assisted surgery has been making its way into the operating room (OR) for decades, boosting minimally invasive general surgery, enhancing orthopaedics, and enabling precision-guided catheter systems—with continued improvements leading to complex systems such as Intuitive’s marke...
CUH neurosurgeon wins prestigious Hunterian Professorship award
A consultant neurosurgeon from Addenbrooke’s Hospital has been given a prestigious award for his cutting-edge research into traumatic brain injury. ...
Tom’s Trust spread Christmas cheer to children in hospital
From superhero capes to books and cuddly soft toys, children were treated to some wonderful gifts from Tom’s Trust while spending time in hospital over the Christmas period. The charity’s psychology team in Newcastle organised the presents for children who were being treated at the Gre...
Arecor announces transfer of AT307 to Hikma
License milestone to develop and commercialise ready-to-use medicine achieved. Arecor regains rights to AT282 following portfolio review at Hikma. ...
Rare Disease: A year in review
As more investments have been made in developing and commercializing treatments for rare diseases, the experience and expertise of our CRA teams have grown. The number of client projects undertaken by CRA consultants in rare diseases now exceeds 600 in the last five years and constitute...
FUJIFILM Irvine Scientific Launches HEK293 Feed, Specifically Designed for Viral Vector Production
Chemically defined, BalanCD HEK293 Viral Feed enhances viral vector production for gene therapy applications and viral vector-based vaccines ...